HC Wainwright Has Positive Outlook for SRTS Q3 Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for Sensus Healthcare in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.08 per share for the quarter, up from their previous estimate of $0.03. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.20 EPS.

Separately, Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Stock Down 0.5 %

Shares of NASDAQ SRTS opened at $8.37 on Wednesday. The stock’s 50 day moving average price is $6.42 and its 200-day moving average price is $6.00. The company has a market capitalization of $137.10 million, a PE ratio of 14.75 and a beta of 1.04. Sensus Healthcare has a twelve month low of $2.02 and a twelve month high of $8.69.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in shares of Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after buying an additional 100,294 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares in the last quarter. Marshall Wace LLP grew its position in shares of Sensus Healthcare by 152.4% in the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares during the period. Acadian Asset Management LLC increased its stake in shares of Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock valued at $239,000 after purchasing an additional 38,474 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Sensus Healthcare during the second quarter valued at $156,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.